PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 7042592-0 1982 The antenatal use of ambroxol (bromhexine metabolite VIII) to prevent hyaline membrane disease: a controlled double-blind study. Ambroxol 21-29 cytochrome c oxidase subunit 8A Homo sapiens 53-57 6688451-1 1983 An experimental study with metabolite VIII of bromhexine (Ambroxol). Ambroxol 58-66 cytochrome c oxidase subunit 8A Homo sapiens 38-42 7042592-1 1982 A prospective double-blind clinical trial was carried out to determine whether ambroxol (bromhexine metabolite VIII) treatment (1000 mg/day for a period of 5 days) reduces the risk of hyaline membrane disease (HMD) in potentially premature infants. Ambroxol 79-87 cytochrome c oxidase subunit 8A Homo sapiens 111-115 33606887-4 2021 Thus, real-world observational data are needed on the safety and efficacy of ambroxol for patients with Gaucher disease (GD) and GBA-Parkinson disease (GBA-PD). Ambroxol 77-85 glucosylceramidase beta Homo sapiens 129-132 1174081-2 1975 Results from experimental studies in animals with the metabolite VIII of bromhexine (N-[trans-4-hydroxy-cyclohexyl]=[2-amino-3,5-dibromo-benzyl]-amine, Ambroxol (NA 842)) are described in order to contribute to the understanding of this substance"s mode of action. Ambroxol 152-160 cytochrome c oxidase subunit 8A Homo sapiens 65-69 581993-0 1978 [Inhalation therapy with the new antisecretory drug ambroxol (metabolite VIII of bromhexine) in otorhinolaryngology]. Ambroxol 52-60 cytochrome c oxidase subunit 8A Homo sapiens 73-77 33606887-13 2021 CONCLUSION: Until the approval of specific therapies for nGD and disease-modification for GBA-PD, these preliminary data may be encouraging to physicians and patients who consider an off-label use of ambroxol. Ambroxol 200-208 glucosylceramidase beta Homo sapiens 90-93 33895135-0 2021 Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. Ambroxol 39-47 sphingomyelin phosphodiesterase 1 Homo sapiens 14-35 33836415-5 2021 In this study, we report two GD3 siblings in whom ambroxol combined with enzyme replacement therapy was initiated at different stages of the disease. Ambroxol 50-58 GRDX Homo sapiens 29-32 33836415-10 2021 This observation suggests that early initiation of ambroxol treatment may arrest neurological involvement in some GD3 patients. Ambroxol 51-59 GRDX Homo sapiens 114-117 33895135-3 2021 The structure of ambroxol, i.e. trans-4-[(2,4-dibromanilin-6-yl)-methyamino]-cyclohexanol, a mucolytic drug applied by inhalation, suggests that the drug might inhibit the acid sphingomyelinase, and thereby infection with SARS-CoV-2. Ambroxol 17-25 sphingomyelin phosphodiesterase 1 Homo sapiens 172-193 33895135-6 2021 We found that entry of pp-VSV-SARS-CoV-2 spike required activation of acid sphingomyelinase and release of ceramide, events that were all prevented by pretreatment with ambroxol. Ambroxol 169-177 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 41-46 33895135-6 2021 We found that entry of pp-VSV-SARS-CoV-2 spike required activation of acid sphingomyelinase and release of ceramide, events that were all prevented by pretreatment with ambroxol. Ambroxol 169-177 sphingomyelin phosphodiesterase 1 Homo sapiens 70-91 33895135-8 2021 Inhalation of ambroxol reduced acid sphingomyelinase activity in nasal epithelial cells, and prevented pp-VSV-SARS-CoV-2 spike-induced acid sphingomyelinase activation, ceramide release, and entry of pp-VSV-SARS-CoV-2 spike ex vivo. Ambroxol 14-22 sphingomyelin phosphodiesterase 1 Homo sapiens 31-52 33895135-8 2021 Inhalation of ambroxol reduced acid sphingomyelinase activity in nasal epithelial cells, and prevented pp-VSV-SARS-CoV-2 spike-induced acid sphingomyelinase activation, ceramide release, and entry of pp-VSV-SARS-CoV-2 spike ex vivo. Ambroxol 14-22 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 121-126 33895135-8 2021 Inhalation of ambroxol reduced acid sphingomyelinase activity in nasal epithelial cells, and prevented pp-VSV-SARS-CoV-2 spike-induced acid sphingomyelinase activation, ceramide release, and entry of pp-VSV-SARS-CoV-2 spike ex vivo. Ambroxol 14-22 sphingomyelin phosphodiesterase 1 Homo sapiens 135-156 33895135-8 2021 Inhalation of ambroxol reduced acid sphingomyelinase activity in nasal epithelial cells, and prevented pp-VSV-SARS-CoV-2 spike-induced acid sphingomyelinase activation, ceramide release, and entry of pp-VSV-SARS-CoV-2 spike ex vivo. Ambroxol 14-22 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 218-223 33895135-9 2021 The addition of purified acid sphingomyelinase or C16 ceramide restored entry of pp-VSV-SARS-CoV-2 spike into ambroxol-treated epithelial cells. Ambroxol 110-118 sphingomyelin phosphodiesterase 1 Homo sapiens 25-46 33895135-9 2021 The addition of purified acid sphingomyelinase or C16 ceramide restored entry of pp-VSV-SARS-CoV-2 spike into ambroxol-treated epithelial cells. Ambroxol 110-118 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 99-104 33609962-6 2021 The results showed that ambroxol treatment significantly increased GCase activity in cultured macrophages derived from patient blood monocytic cell (PBMC) of GD (by 3.3-fold) and GBA-PD patients (by 3.5-fold) compared to untreated cells (p < 0.0001 and p < 0.0001, respectively) four days after cultivation. Ambroxol 24-32 glucosylceramidase beta Homo sapiens 179-182 33924075-6 2021 mRNA expression levels of several cytokines, including interleukin 12 (IL-12), IL-23, IL-17F, interferon gamma (IFN-gamma), and surfactant protein (SP)-A, increased in infected mice treated with Ax. Ambroxol 195-197 interferon gamma Mus musculus 94-121 33924075-6 2021 mRNA expression levels of several cytokines, including interleukin 12 (IL-12), IL-23, IL-17F, interferon gamma (IFN-gamma), and surfactant protein (SP)-A, increased in infected mice treated with Ax. Ambroxol 195-197 surfactant associated protein A1 Mus musculus 128-153 33924075-7 2021 The IFN-gamma protein expression levels were also significantly higher in infected and Ax-treated mice. Ambroxol 87-89 interferon gamma Mus musculus 4-13 33609962-7 2021 Ambroxol treatment significantly reduced HexSph concentration in GD (by 2.1-fold) and GBA-PD patients (by 1.6-fold) (p < 0.0001 and p < 0.0001, respectively). Ambroxol 0-8 glucosylceramidase beta Homo sapiens 86-89 33332729-5 2021 Receptor antagonism and genetic depletion studies revealed P2X2 as the relevant ATP receptor and pharmacological screenings identified ambroxol as a novel P2X2 antagonist. Ambroxol 135-143 purinergic receptor P2X 2 Homo sapiens 80-92 33551744-0 2020 Ambroxol Upregulates Glucocerebrosidase Expression to Promote Neural Stem Cells Differentiation Into Neurons Through Wnt/beta-Catenin Pathway After Ischemic Stroke. Ambroxol 0-8 catenin beta 1 Homo sapiens 121-133 33551744-5 2020 The potential mechanism, to some extent, was due to promoting NSCs differentiation into neurons and interfering NSCs differentiation into astrocytes through increasing GCase expression to activate Wnt/beta-catenin signaling pathway in penumbra after ischemic stroke, which advanced basic knowledge of ambroxol in regulating NSCs differentiation and provided a feasible therapy for ischemic stroke treatment, even in other brain disorders in clinic. Ambroxol 301-309 catenin beta 1 Homo sapiens 201-213 33045350-0 2020 Azithromycin and Ambroxol as potential pharmacotherapy for ARS-CoV-2. Ambroxol 17-25 RIEG2 Homo sapiens 59-62 32067531-2 2020 Ambroxol-carrageenan (ABX-CRG) complexation was studied for the optimum binding capacity, which was used to prepare the complex by kneading and co-precipitation. Ambroxol 0-8 chromodomain helicase DNA binding protein 7 Homo sapiens 26-29 32739173-7 2020 Ambroxol, a chaperone molecule that inhibits GBA2, has been shown to have beneficial effects by slowing the development of the disease in SOD1G86R mice. Ambroxol 0-8 glucosidase beta 2 Mus musculus 45-49 32741259-8 2020 Based on better dock score, binding-free energy and binding interactions compared to the control molecules, six molecules (Neohesperidin, Myricitrin, Quercitrin, Naringin, Icariin, and Ambroxol) were found to be promising against the TMPRSS2. Ambroxol 185-193 transmembrane serine protease 2 Homo sapiens 234-241 32309438-6 2020 The possible mechanism might be due to suppressing endoplasmic reticulum stress involving the IRE1alpha/TRAF2 signaling pathway, which paves a new path for the treatment of ICH and opens a new window for the use of ambroxol in clinical practice. Ambroxol 215-223 endoplasmic reticulum to nucleus signaling 1 Homo sapiens 94-103 32612253-6 2020 For example, the local anesthetics ambroxol and lidocaine block both NaV1.7 and NaChBac but affect activation and inactivation of the two channels to different extents. Ambroxol 35-43 sodium voltage-gated channel alpha subunit 9 Homo sapiens 69-75 31994807-4 2020 In addition, as has recently been shown, ambroxol is a Nav 1.8 channel blocker in Abeta, Adelta, and unmyelinated C-fibers, and therefore reduces the transmission of sensory stimuli from the primary afferent neurons to the dorsal spinal cord. Ambroxol 41-49 sodium voltage-gated channel alpha subunit 10 Homo sapiens 55-62 31930374-2 2020 In vitro and in vivo studies have reported that ambroxol increases beta-glucocerebrosidase (GCase) enzyme activity and reduces alpha-synuclein levels. Ambroxol 48-56 glucosylceramidase beta Homo sapiens 67-90 31930374-2 2020 In vitro and in vivo studies have reported that ambroxol increases beta-glucocerebrosidase (GCase) enzyme activity and reduces alpha-synuclein levels. Ambroxol 48-56 synuclein alpha Homo sapiens 127-142 31930374-19 2020 Conclusions and Relevance: The study results suggest that ambroxol therapy was safe and well tolerated; CSF penetration and target engagement of ambroxol were achieved, and CSF alpha-synuclein levels were increased. Ambroxol 58-66 synuclein alpha Homo sapiens 177-192 32309438-6 2020 The possible mechanism might be due to suppressing endoplasmic reticulum stress involving the IRE1alpha/TRAF2 signaling pathway, which paves a new path for the treatment of ICH and opens a new window for the use of ambroxol in clinical practice. Ambroxol 215-223 TNF receptor associated factor 2 Homo sapiens 104-109 31822786-3 2020 Ambroxol (ABX), an approved cough-suppressant, was identified as an enzyme-enhancement agent of the residual activity of glucocerebrosidase mutants derived from different misfolding-mutations in the GBA gene. Ambroxol 0-8 glucosylceramidase beta Homo sapiens 199-202 31822786-3 2020 Ambroxol (ABX), an approved cough-suppressant, was identified as an enzyme-enhancement agent of the residual activity of glucocerebrosidase mutants derived from different misfolding-mutations in the GBA gene. Ambroxol 10-13 glucosylceramidase beta Homo sapiens 199-202 31210340-10 2019 RESULTS: Ambroxol at 50 mg/kg inhibited ventilation-induced lung inflammation, significantly elevated the ventilation-induced down-regulation of gamma-GCS mRNA and protein, and significantly decreased the ventilation-induced up-regulation of c-Jun mRNA and protein. Ambroxol 9-17 glutamate-cysteine ligase, catalytic subunit Rattus norvegicus 145-154 31654086-7 2020 Ambroxol restored TH and DAT levels on D-71 as the markers of dopaminergic cell and extracellular DA concentration respectively, indicating the recovery of dopaminergic system. Ambroxol 0-8 solute carrier family 6 member 3 Rattus norvegicus 25-28 31654086-8 2020 Factors involved in PD pathogenesis such as GCase enzymatic and mitochondrial complex-I activity were restored, and alpha-synuclein pathology was decreased by ambroxol. Ambroxol 159-167 synuclein alpha Rattus norvegicus 116-131 31654086-11 2020 Therefore, both the GCase-stimulating and alpha-synuclein pathology-diminishing effects of ambroxol may be responsible for increment in mitochondrial function and restoration of dopaminergic system. Ambroxol 91-99 synuclein alpha Rattus norvegicus 42-57 31222941-0 2019 Scaffolds for Sustained Release of Ambroxol Hydrochloride, a Pharmacological Chaperone That Increases the Activity of Misfolded beta-Glucocerebrosidase. Ambroxol 35-57 glucosylceramidase beta Homo sapiens 128-151 31222941-1 2019 Ambroxol is a pharmacological chaperone (PC) for Gaucher disease that increases lysosomal activity of misfolded beta-glucocerebrosidase (GCase) while displaying a safe toxicological profile. Ambroxol 0-8 glucosylceramidase beta Homo sapiens 112-135 31222941-1 2019 Ambroxol is a pharmacological chaperone (PC) for Gaucher disease that increases lysosomal activity of misfolded beta-glucocerebrosidase (GCase) while displaying a safe toxicological profile. Ambroxol 0-8 glucosylceramidase beta Homo sapiens 137-142 31210340-12 2019 CONCLUSIONS: Ambroxol increases gamma-GCS to promote GSH production, which in turn, inhibits ROS-dependent AP-1 activation and inflammation. Ambroxol 13-21 glutamate-cysteine ligase, catalytic subunit Rattus norvegicus 32-41 31210340-12 2019 CONCLUSIONS: Ambroxol increases gamma-GCS to promote GSH production, which in turn, inhibits ROS-dependent AP-1 activation and inflammation. Ambroxol 13-21 Jun proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 107-111 30895504-11 2019 Pretreatment with AMB prevented the elevation of malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-alpha) level, reduction of total glutathione (GSH) that induced by CYP. Ambroxol 18-21 tumor necrosis factor Mus musculus 75-102 30933843-5 2019 Moreover, with ambroxol intervention, the levels of antioxidants glutathione (GSH), superoxide dismutase (SOD), and IL-10 were found to be increased along with a reduction in nitrite levels in skin tissues. Ambroxol 15-23 superoxide dismutase 1, soluble Mus musculus 106-109 30933843-5 2019 Moreover, with ambroxol intervention, the levels of antioxidants glutathione (GSH), superoxide dismutase (SOD), and IL-10 were found to be increased along with a reduction in nitrite levels in skin tissues. Ambroxol 15-23 interleukin 10 Mus musculus 116-121 30933843-6 2019 On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1beta, IL-6, IL-17, IL-22, IL-23, TGF-beta, and TNF-alpha. Ambroxol 19-27 interleukin 1 beta Mus musculus 119-127 30933843-6 2019 On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1beta, IL-6, IL-17, IL-22, IL-23, TGF-beta, and TNF-alpha. Ambroxol 19-27 interleukin 6 Mus musculus 129-133 30933843-6 2019 On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1beta, IL-6, IL-17, IL-22, IL-23, TGF-beta, and TNF-alpha. Ambroxol 19-27 interleukin 17A Mus musculus 135-140 30933843-6 2019 On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1beta, IL-6, IL-17, IL-22, IL-23, TGF-beta, and TNF-alpha. Ambroxol 19-27 interleukin 22 Mus musculus 142-147 30933843-6 2019 On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1beta, IL-6, IL-17, IL-22, IL-23, TGF-beta, and TNF-alpha. Ambroxol 19-27 interleukin 23, alpha subunit p19 Mus musculus 149-154 30933843-6 2019 On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1beta, IL-6, IL-17, IL-22, IL-23, TGF-beta, and TNF-alpha. Ambroxol 19-27 transforming growth factor, beta 1 Mus musculus 156-164 30933843-6 2019 On the other hand, ambroxol treatment significantly reduced imiquimod-induced levels of inflammatory cytokines such as IL-1beta, IL-6, IL-17, IL-22, IL-23, TGF-beta, and TNF-alpha. Ambroxol 19-27 tumor necrosis factor Mus musculus 170-179 30933843-7 2019 Furthermore, from immunoblotting, we found a decrease in the protein expression of nitrotyrosine, iNOS, NF-kappaB and MAPKs signaling cascade with a concomitant increase in the expression of Nrf-2 and SOD-1 in RAW 264.7 cells and skin tissues by ambroxol. Ambroxol 246-254 nitric oxide synthase 2, inducible Mus musculus 98-102 30933843-7 2019 Furthermore, from immunoblotting, we found a decrease in the protein expression of nitrotyrosine, iNOS, NF-kappaB and MAPKs signaling cascade with a concomitant increase in the expression of Nrf-2 and SOD-1 in RAW 264.7 cells and skin tissues by ambroxol. Ambroxol 246-254 nuclear factor, erythroid derived 2, like 2 Mus musculus 191-196 30933843-7 2019 Furthermore, from immunoblotting, we found a decrease in the protein expression of nitrotyrosine, iNOS, NF-kappaB and MAPKs signaling cascade with a concomitant increase in the expression of Nrf-2 and SOD-1 in RAW 264.7 cells and skin tissues by ambroxol. Ambroxol 246-254 superoxide dismutase 1, soluble Mus musculus 201-206 30933843-9 2019 Moreover, ambroxol downregulated the ICAM-1 and Ki67 expression observed in skin tissues. Ambroxol 10-18 intercellular adhesion molecule 1 Mus musculus 37-43 30933843-9 2019 Moreover, ambroxol downregulated the ICAM-1 and Ki67 expression observed in skin tissues. Ambroxol 10-18 antigen identified by monoclonal antibody Ki 67 Mus musculus 48-52 30895504-11 2019 Pretreatment with AMB prevented the elevation of malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-alpha) level, reduction of total glutathione (GSH) that induced by CYP. Ambroxol 18-21 tumor necrosis factor Mus musculus 104-113 30040928-0 2018 Ambroxol modulates 6-Hydroxydopamine-induced temporal reduction in Glucocerebrosidase (GCase) enzymatic activity and Parkinson"s disease symptoms. Ambroxol 0-8 glucosylceramidase beta Rattus norvegicus 87-92 32186024-5 2019 RESULTS: The number of inflammatory cells in the BALF and TNF-alpha, IL-8 and IL-6 level in plasma were significantly reduced in rats with COPD when treated with Daiqin phlegm-expelling pill or ambroxol hydrochloride tablet, compared with those without any treatment. Ambroxol 194-216 tumor necrosis factor Rattus norvegicus 58-67 32186024-5 2019 RESULTS: The number of inflammatory cells in the BALF and TNF-alpha, IL-8 and IL-6 level in plasma were significantly reduced in rats with COPD when treated with Daiqin phlegm-expelling pill or ambroxol hydrochloride tablet, compared with those without any treatment. Ambroxol 194-216 interleukin 6 Rattus norvegicus 78-82 30383980-0 2019 Ambroxol attenuates cisplatin-induced hepatotoxicity and nephrotoxicity via inhibition of p-JNK/p-ERK. Ambroxol 0-8 eukaryotic translation initiation factor 2 alpha kinase 3 Homo sapiens 96-101 30383980-7 2019 Ambroxol mitigated cisplatin inflammatory damage by inhibition of tumor necrosis factor-alpha, interleukin-1beta, and nuclear factor kappa-B and elevation of nuclear factor erythroid 2-related factor 2. Ambroxol 0-8 tumor necrosis factor Homo sapiens 66-93 30383980-7 2019 Ambroxol mitigated cisplatin inflammatory damage by inhibition of tumor necrosis factor-alpha, interleukin-1beta, and nuclear factor kappa-B and elevation of nuclear factor erythroid 2-related factor 2. Ambroxol 0-8 interleukin 1 beta Homo sapiens 95-112 30383980-7 2019 Ambroxol mitigated cisplatin inflammatory damage by inhibition of tumor necrosis factor-alpha, interleukin-1beta, and nuclear factor kappa-B and elevation of nuclear factor erythroid 2-related factor 2. Ambroxol 0-8 NFE2 like bZIP transcription factor 2 Homo sapiens 158-201 30383980-8 2019 Moreover, ambroxol inhibited oxidative damage indicated by reduction of malondialdehyde and replenished the store of reduced glutathione likely by upregulating glutathione reductase and superoxide dismutase. Ambroxol 10-18 glutathione-disulfide reductase Homo sapiens 160-181 30383980-9 2019 Elevation of phosphorylated c-Jun N-terminal kinases (p-JNK) and phosphorylated extracellular signal-regulated kinase (p-ERK) were attenuated by ambroxol associated with a decrease in the expression of caspase-3; these results were consistent with histopathological results. Ambroxol 145-153 eukaryotic translation initiation factor 2 alpha kinase 3 Homo sapiens 119-124 30383980-9 2019 Elevation of phosphorylated c-Jun N-terminal kinases (p-JNK) and phosphorylated extracellular signal-regulated kinase (p-ERK) were attenuated by ambroxol associated with a decrease in the expression of caspase-3; these results were consistent with histopathological results. Ambroxol 145-153 caspase 3 Homo sapiens 202-211 30662625-3 2018 As a novel approach for the treatment of Gaucher disease (GD), ambroxol was recently identified as a chaperone for GD, caused by the pathogenic variants in GBA gene, resulting in lysosomal enzyme glucocerebrosidase (GCase) deficiency. Ambroxol 63-71 glucosylceramidase beta Homo sapiens 156-159 30662625-6 2018 Ambroxol enhanced GCase activity in cells with wild type GBA and in those, compound heterozygous for N370S, but was ineffective in cell lines with complex GBA alleles. Ambroxol 0-8 glucosylceramidase beta Homo sapiens 57-60 30119265-13 2018 Molecular docking model predicts preferential binding of ambroxol to mouse Nav1.6, Nav1.9 channels. Ambroxol 57-65 sodium channel, voltage-gated, type VIII, alpha Mus musculus 75-81 30119265-13 2018 Molecular docking model predicts preferential binding of ambroxol to mouse Nav1.6, Nav1.9 channels. Ambroxol 57-65 sodium channel, voltage-gated, type XI, alpha Mus musculus 83-89 29400127-9 2018 Clinical trials of ambroxol, a glucocerebrosidase chaperone, are currently ongoing in PD and PD dementia, as is a trial of substrate reduction therapy. Ambroxol 19-27 glucosylceramidase beta Homo sapiens 31-49 30040928-11 2018 Therefore, the regenerative effects of AMB in dopamine toxicity may be due to its effects on GCase activity and mitochondrial function. Ambroxol 39-42 glucosylceramidase beta Rattus norvegicus 93-98 30040928-4 2018 Ambroxol (AMB) is reported to increase GCase activity in different brain-regions. Ambroxol 0-8 glucosylceramidase beta Rattus norvegicus 39-44 30040928-4 2018 Ambroxol (AMB) is reported to increase GCase activity in different brain-regions. Ambroxol 10-13 glucosylceramidase beta Rattus norvegicus 39-44 29362387-7 2018 Transcription factor EB (TFEB), the master regulator of the CLEAR pathway involved in lysosomal biogenesis was also increased upon ambroxol treatment. Ambroxol 131-139 transcription factor EB Mus musculus 25-29 29735266-11 2018 Ambroxol did not improve insulin sensitivity in obese insulin-resistant CathAS190A-Neo mice indicating that the Ambroxol effect is mediated through NEU1 induction. Ambroxol 112-120 neuraminidase 1 Mus musculus 148-152 29412172-6 2018 KEY FINDINGS: These studies indicate that ambroxol has affinity for the 5-HT3 serotonin receptor, as well as affinity for the 5-HT serotonin transporter (SERT), with IC50 values of 17,600 nM and 19,500 nM respectively. Ambroxol 42-50 sodium-dependent serotonin transporter Cavia porcellus 131-152 29412172-6 2018 KEY FINDINGS: These studies indicate that ambroxol has affinity for the 5-HT3 serotonin receptor, as well as affinity for the 5-HT serotonin transporter (SERT), with IC50 values of 17,600 nM and 19,500 nM respectively. Ambroxol 42-50 sodium-dependent serotonin transporter Cavia porcellus 154-158 29412172-8 2018 SIGNIFICANCE: Together, these studies indicate that ambroxol may exert its beneficial properties via antagonism of the 5-HT3 serotonin receptor and/or inhibition of serotonin uptake (5-HT transport: SERT), in addition to its reported effects at the sodium channel and guanylate cyclase. Ambroxol 52-60 sodium-dependent serotonin transporter Cavia porcellus 199-203 29362387-7 2018 Transcription factor EB (TFEB), the master regulator of the CLEAR pathway involved in lysosomal biogenesis was also increased upon ambroxol treatment. Ambroxol 131-139 transcription factor EB Mus musculus 0-23 29362387-10 2018 Mitochondria content was also found to be increased by ambroxol via peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-alpha). Ambroxol 55-63 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 68-136 29362387-10 2018 Mitochondria content was also found to be increased by ambroxol via peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-alpha). Ambroxol 55-63 peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Mus musculus 138-148 29362387-11 2018 Our data suggest that ambroxol, besides being a GCase chaperone, also acts on other pathways, such as mitochondria, lysosomal biogenesis, and the secretory pathway. Ambroxol 22-30 glucosidase, beta, acid Mus musculus 48-53 29441886-10 2017 In addition, we found that Mucosolvan inhibited cell apoptosis and NF-kappaB pathway activation and effectively improved pulmonary functions. Ambroxol 27-37 nuclear factor kappa B subunit 1 Homo sapiens 68-77 26872986-0 2016 Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1/2 signaling pathway. Ambroxol 0-8 mitogen-activated protein kinase 3 Homo sapiens 96-135 28741230-6 2017 Disease-modifying approaches are aimed at preventing, slowing or ameliorating the production, aggregation and deposition of pathological proteins, including immunotherapy targeting alpha-synuclein and an ongoing trial using ambroxol which increases glucocerebrosidase activity to lower the levels of the protein alpha-synuclein. Ambroxol 224-232 synuclein alpha Homo sapiens 312-327 28444776-1 2017 The antifungal effects of ambroxol (Amb; the metabolite VIII of bromhexine) against Cryptococcus planktonic cells and mature biofilms were investigated in this study. Ambroxol 26-34 cytochrome c oxidase subunit 8A Homo sapiens 56-60 28295625-3 2017 Ambroxol is a small molecule chaperone that has been shown in mice to cross the blood-brain barrier, increase GCase activity and reduce alpha-synuclein protein levels. Ambroxol 0-8 glucosidase, beta, acid Mus musculus 110-115 28295625-3 2017 Ambroxol is a small molecule chaperone that has been shown in mice to cross the blood-brain barrier, increase GCase activity and reduce alpha-synuclein protein levels. Ambroxol 0-8 synuclein, alpha Mus musculus 136-151 28295625-4 2017 In this study, we analyze the effect of ambroxol treatment on GCase activity in healthy nonhuman primates. Ambroxol 40-48 glucosidase, beta, acid Mus musculus 62-67 28295625-5 2017 We show that daily administration of ambroxol results in increased brain GCase activity. Ambroxol 37-45 glucosidase, beta, acid Mus musculus 73-78 27859541-0 2016 Ambroxol effects in glucocerebrosidase and alpha-synuclein transgenic mice. Ambroxol 0-8 synuclein, alpha Mus musculus 43-58 27859541-9 2016 RESULTS: Ambroxol treatment resulted in increased brain glucocerebrosidase activity in (1) wild-type mice, (2) transgenic mice expressing the heterozygous L444P mutation in the murine glucocerebrosidase 1 gene, and (3) transgenic mice overexpressing human alpha-synuclein. Ambroxol 9-17 synuclein alpha Homo sapiens 256-271 27859541-10 2016 Furthermore, in the mice overexpressing human alpha-synuclein, ambroxol treatment decreased both alpha-synuclein and phosphorylated alpha-synuclein protein levels. Ambroxol 63-71 synuclein alpha Homo sapiens 46-61 27859541-10 2016 Furthermore, in the mice overexpressing human alpha-synuclein, ambroxol treatment decreased both alpha-synuclein and phosphorylated alpha-synuclein protein levels. Ambroxol 63-71 synuclein alpha Homo sapiens 97-112 27859541-10 2016 Furthermore, in the mice overexpressing human alpha-synuclein, ambroxol treatment decreased both alpha-synuclein and phosphorylated alpha-synuclein protein levels. Ambroxol 63-71 synuclein alpha Homo sapiens 97-112 27859541-11 2016 INTERPRETATION: Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease alpha-synuclein and phosphorylated alpha-synuclein protein levels. Ambroxol 55-63 synuclein alpha Homo sapiens 264-279 27859541-11 2016 INTERPRETATION: Our work supports the proposition that ambroxol should be further investigated as a potential novel disease-modifying therapy for treatment of Parkinson disease and neuronopathic Gaucher disease to increase glucocerebrosidase activity and decrease alpha-synuclein and phosphorylated alpha-synuclein protein levels. Ambroxol 55-63 synuclein alpha Homo sapiens 299-314 26881857-0 2016 Inhalation of ambroxol inhibits cigarette smoke-induced acute lung injury in a mouse model by inhibiting the Erk pathway. Ambroxol 14-22 mitogen-activated protein kinase 1 Mus musculus 109-112 26881857-6 2016 The effect of ambroxol on the expression of mucoprotein 5 AC (MUC5AC) and proinflammatory cytokines in NCI-H292 cells stimulated with cigarette smoke extract (CSE). Ambroxol 14-22 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 44-60 26881857-6 2016 The effect of ambroxol on the expression of mucoprotein 5 AC (MUC5AC) and proinflammatory cytokines in NCI-H292 cells stimulated with cigarette smoke extract (CSE). Ambroxol 14-22 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 62-68 26881857-7 2016 Four days of daily inhalation of ambroxol at 3.75 or 7.5mg/ml for 20 min suppressed the accumulation of neutrophils and macrophages in the bronchoalveolar lavage fluid (BALF) and lung tissues, and inhibited increases in the mRNA and protein levels of tumor necrosis factor (TNF)-alpha, CCL-2 and KC, but not interleukin (IL)-1beta in the CS-exposed mice. Ambroxol 33-41 tumor necrosis factor Mus musculus 251-284 26881857-7 2016 Four days of daily inhalation of ambroxol at 3.75 or 7.5mg/ml for 20 min suppressed the accumulation of neutrophils and macrophages in the bronchoalveolar lavage fluid (BALF) and lung tissues, and inhibited increases in the mRNA and protein levels of tumor necrosis factor (TNF)-alpha, CCL-2 and KC, but not interleukin (IL)-1beta in the CS-exposed mice. Ambroxol 33-41 chemokine (C-C motif) ligand 2 Mus musculus 286-291 26881857-7 2016 Four days of daily inhalation of ambroxol at 3.75 or 7.5mg/ml for 20 min suppressed the accumulation of neutrophils and macrophages in the bronchoalveolar lavage fluid (BALF) and lung tissues, and inhibited increases in the mRNA and protein levels of tumor necrosis factor (TNF)-alpha, CCL-2 and KC, but not interleukin (IL)-1beta in the CS-exposed mice. Ambroxol 33-41 interleukin 1 beta Mus musculus 308-330 26881857-11 2016 Using cultured lung epithelial cells, we demonstrated that pretreatment with ambroxol at 2 or 20 muM inhibited the CSE-induced up-regulation of MUC5AC, TNF-alpha, IL-1beta mRNA levels, which was through inhibiting Erk signaling pathway. Ambroxol 77-85 mucin 5, subtypes A and C, tracheobronchial/gastric Mus musculus 144-150 26881857-11 2016 Using cultured lung epithelial cells, we demonstrated that pretreatment with ambroxol at 2 or 20 muM inhibited the CSE-induced up-regulation of MUC5AC, TNF-alpha, IL-1beta mRNA levels, which was through inhibiting Erk signaling pathway. Ambroxol 77-85 tumor necrosis factor Mus musculus 152-161 26881857-11 2016 Using cultured lung epithelial cells, we demonstrated that pretreatment with ambroxol at 2 or 20 muM inhibited the CSE-induced up-regulation of MUC5AC, TNF-alpha, IL-1beta mRNA levels, which was through inhibiting Erk signaling pathway. Ambroxol 77-85 interleukin 1 beta Mus musculus 163-171 26881857-11 2016 Using cultured lung epithelial cells, we demonstrated that pretreatment with ambroxol at 2 or 20 muM inhibited the CSE-induced up-regulation of MUC5AC, TNF-alpha, IL-1beta mRNA levels, which was through inhibiting Erk signaling pathway. Ambroxol 77-85 mitogen-activated protein kinase 1 Mus musculus 214-217 27340385-10 2016 In vitro, ambroxol increased levels of IL-10, IFN-gamma, and IL-12 from Lung MNCs and AM, whereas IL-4, IL-5, and IL-13 production was not altered. Ambroxol 10-18 interleukin 10 Mus musculus 39-44 27340385-10 2016 In vitro, ambroxol increased levels of IL-10, IFN-gamma, and IL-12 from Lung MNCs and AM, whereas IL-4, IL-5, and IL-13 production was not altered. Ambroxol 10-18 interferon gamma Mus musculus 46-55 27340385-11 2016 Taken together, ambroxol was effective in preventing AHR and airway inflammation through upregulation of Th1 cytokines and protection from oxidative stress in the airways. Ambroxol 16-24 negative elongation factor complex member C/D, Th1l Mus musculus 105-108 26872986-5 2016 Our results demonstrated that ambroxol administered by inhalation inhibited MUC5AC expression, reduced glycosaminoglycan levels, enhanced the function of mucociliary clearance and promoted sputum excretion, suggesting that ambroxol increases expectoration of sputum by reducing its viscosity. Ambroxol 30-38 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 76-82 26872986-6 2016 Moreover, ambroxol significantly alleviated LPS-induced the influx of inflammatory cells and the extracellular signal-regulated kinase 1/2 (Erk 1/2) expression in lung tissues, and inhibited increases in the mRNA expression of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, CCL-2 (monocyte chemotactic protein-1), KC (keratinocyte cell protein) and interleukin (IL)-1beta in lung tissues. Ambroxol 10-18 mitogen-activated protein kinase 3 Homo sapiens 97-138 26872986-6 2016 Moreover, ambroxol significantly alleviated LPS-induced the influx of inflammatory cells and the extracellular signal-regulated kinase 1/2 (Erk 1/2) expression in lung tissues, and inhibited increases in the mRNA expression of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, CCL-2 (monocyte chemotactic protein-1), KC (keratinocyte cell protein) and interleukin (IL)-1beta in lung tissues. Ambroxol 10-18 mitogen-activated protein kinase 3 Homo sapiens 140-147 26872986-6 2016 Moreover, ambroxol significantly alleviated LPS-induced the influx of inflammatory cells and the extracellular signal-regulated kinase 1/2 (Erk 1/2) expression in lung tissues, and inhibited increases in the mRNA expression of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, CCL-2 (monocyte chemotactic protein-1), KC (keratinocyte cell protein) and interleukin (IL)-1beta in lung tissues. Ambroxol 10-18 tumor necrosis factor Homo sapiens 258-291 26872986-6 2016 Moreover, ambroxol significantly alleviated LPS-induced the influx of inflammatory cells and the extracellular signal-regulated kinase 1/2 (Erk 1/2) expression in lung tissues, and inhibited increases in the mRNA expression of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, CCL-2 (monocyte chemotactic protein-1), KC (keratinocyte cell protein) and interleukin (IL)-1beta in lung tissues. Ambroxol 10-18 C-C motif chemokine ligand 2 Homo sapiens 293-298 26872986-6 2016 Moreover, ambroxol significantly alleviated LPS-induced the influx of inflammatory cells and the extracellular signal-regulated kinase 1/2 (Erk 1/2) expression in lung tissues, and inhibited increases in the mRNA expression of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, CCL-2 (monocyte chemotactic protein-1), KC (keratinocyte cell protein) and interleukin (IL)-1beta in lung tissues. Ambroxol 10-18 C-C motif chemokine ligand 2 Homo sapiens 300-330 26872986-6 2016 Moreover, ambroxol significantly alleviated LPS-induced the influx of inflammatory cells and the extracellular signal-regulated kinase 1/2 (Erk 1/2) expression in lung tissues, and inhibited increases in the mRNA expression of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha, CCL-2 (monocyte chemotactic protein-1), KC (keratinocyte cell protein) and interleukin (IL)-1beta in lung tissues. Ambroxol 10-18 interleukin 1 beta Homo sapiens 368-390 26872986-9 2016 In addition, we found that ambroxol dose-dependently inhibited LPS-induced increases in the mRNA expression of MUC5AC, TNF-alpha, and IL-1beta in human bronchial epithelial cell (NCI-H292) by inhibiting the Erk signaling pathway. Ambroxol 27-35 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 111-117 26872986-9 2016 In addition, we found that ambroxol dose-dependently inhibited LPS-induced increases in the mRNA expression of MUC5AC, TNF-alpha, and IL-1beta in human bronchial epithelial cell (NCI-H292) by inhibiting the Erk signaling pathway. Ambroxol 27-35 tumor necrosis factor Homo sapiens 119-128 26872986-9 2016 In addition, we found that ambroxol dose-dependently inhibited LPS-induced increases in the mRNA expression of MUC5AC, TNF-alpha, and IL-1beta in human bronchial epithelial cell (NCI-H292) by inhibiting the Erk signaling pathway. Ambroxol 27-35 interleukin 1 beta Homo sapiens 134-142 26872986-9 2016 In addition, we found that ambroxol dose-dependently inhibited LPS-induced increases in the mRNA expression of MUC5AC, TNF-alpha, and IL-1beta in human bronchial epithelial cell (NCI-H292) by inhibiting the Erk signaling pathway. Ambroxol 27-35 mitogen-activated protein kinase 1 Homo sapiens 207-210 26094596-0 2015 Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson"s disease cells. Ambroxol 0-8 scavenger receptor class B member 2 Homo sapiens 85-91 26611525-9 2016 Aspect of patients, 0.45% NaCl group and 0.9% NaCl+ambroxol group were significantly different in the levels of SP-A, IL-6, IL-8 and TNF-alpha (P<0.01). Ambroxol 51-59 surfactant protein A1 Homo sapiens 112-116 26611525-9 2016 Aspect of patients, 0.45% NaCl group and 0.9% NaCl+ambroxol group were significantly different in the levels of SP-A, IL-6, IL-8 and TNF-alpha (P<0.01). Ambroxol 51-59 tumor necrosis factor Homo sapiens 133-142 26589711-10 2015 The pain reduction achieved individually following ambroxol cream was 2-8 points (NRS) within 5-30 min and lasted for 3-8 h. Pain attacks were reduced in all five patients presenting with this problem. Ambroxol 51-59 sphingolipid transporter 1 (putative) Homo sapiens 82-85 26589711-13 2015 CONCLUSION: Ambroxol acts as a strong local anaesthetic and preferentially inhibits the nociceptively relevant sodium channel subtype Nav 1.8. Ambroxol 12-20 sodium voltage-gated channel alpha subunit 10 Homo sapiens 134-141 26597641-4 2015 Ambroxol preferentially inhibits the channel subtype Nav 1.8, which is expressed particularly in nociceptive C fibers. Ambroxol 0-8 sodium voltage-gated channel alpha subunit 10 Homo sapiens 53-60 26597641-13 2015 CONCLUSION: Ambroxol acts as a strong local anesthetic and preferentially inhibits the nociceptive-relevant sodium channel subtype Nav 1.8. Ambroxol 12-20 sodium voltage-gated channel alpha subunit 10 Homo sapiens 131-138 26094596-0 2015 Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson"s disease cells. Ambroxol 0-8 glucosylceramidase beta Homo sapiens 116-120 26094596-6 2015 GCase activity was reduced in fibroblasts from GBA1-mutant patients and ambroxol corrected this defect. Ambroxol 72-80 glucosylceramidase beta Homo sapiens 47-51 26094596-7 2015 Ambroxol increased cathepsin D activity, GCase and Sap C protein levels in all groups, while LIMP-2 levels were increased only in GBA1-mutant PD fibroblasts. Ambroxol 0-8 cathepsin D Homo sapiens 19-30 25409744-7 2015 We discovered that the expectorant Ambroxol when used in conjunction with known PC resulted in a significant enhancement of mutant alpha-galactosidase A and GAA activities. Ambroxol 35-43 galactosidase alpha Homo sapiens 131-152 25409744-7 2015 We discovered that the expectorant Ambroxol when used in conjunction with known PC resulted in a significant enhancement of mutant alpha-galactosidase A and GAA activities. Ambroxol 35-43 alpha glucosidase Homo sapiens 157-160 25998443-4 2015 OBJECTIVES: We evaluated the ability of ambroxol and/or beclomethasone dipropionate to inhibit LPS-induced expression/release of RANTES, IL-8, inducible NO synthase (iNOS), myeloperoxidase (MPO) and 3-nitrotyrosine (3-NT: nitrosative stress biomarker) in BEAS-2B +- PMNs stimulated with LPS (1 mug/ml). Ambroxol 40-48 C-C motif chemokine ligand 5 Homo sapiens 129-135 25998443-5 2015 METHODS: The effect of ambroxol and/or beclomethasone dipropionate on IL-8, RANTES and iNOS levels was assessed by Western blot analysis; IL-8, MPO and 3-NT levels were measured by ELISA. Ambroxol 23-31 C-X-C motif chemokine ligand 8 Homo sapiens 70-74 25998443-4 2015 OBJECTIVES: We evaluated the ability of ambroxol and/or beclomethasone dipropionate to inhibit LPS-induced expression/release of RANTES, IL-8, inducible NO synthase (iNOS), myeloperoxidase (MPO) and 3-nitrotyrosine (3-NT: nitrosative stress biomarker) in BEAS-2B +- PMNs stimulated with LPS (1 mug/ml). Ambroxol 40-48 C-X-C motif chemokine ligand 8 Homo sapiens 137-141 25998443-5 2015 METHODS: The effect of ambroxol and/or beclomethasone dipropionate on IL-8, RANTES and iNOS levels was assessed by Western blot analysis; IL-8, MPO and 3-NT levels were measured by ELISA. Ambroxol 23-31 C-C motif chemokine ligand 5 Homo sapiens 76-82 25998443-4 2015 OBJECTIVES: We evaluated the ability of ambroxol and/or beclomethasone dipropionate to inhibit LPS-induced expression/release of RANTES, IL-8, inducible NO synthase (iNOS), myeloperoxidase (MPO) and 3-nitrotyrosine (3-NT: nitrosative stress biomarker) in BEAS-2B +- PMNs stimulated with LPS (1 mug/ml). Ambroxol 40-48 nitric oxide synthase 2 Homo sapiens 143-164 25998443-5 2015 METHODS: The effect of ambroxol and/or beclomethasone dipropionate on IL-8, RANTES and iNOS levels was assessed by Western blot analysis; IL-8, MPO and 3-NT levels were measured by ELISA. Ambroxol 23-31 nitric oxide synthase 2 Homo sapiens 87-91 25174313-6 2014 Treatment with high doses of ambroxol appeared to reduce serum tumor necrosis factor-alpha level (WMD -7.92 microg/L; 95% CI, -10.94 to -4.9) and interleukin-6 level (WMD = -20.65 microg/L, 95% CI: -24.74 to -16.55) and to increase serum superoxide dismutase level (WMD = 19.07 NU/mL, 95% CI: 6.16-31.97). Ambroxol 29-37 tumor necrosis factor Homo sapiens 63-90 25998443-8 2015 Ambroxol suppressed LPS-induced RANTES expression and IL-8 release (p < 0.001), whilst inhibiting iNOS expression (p < 0.05). Ambroxol 0-8 C-C motif chemokine ligand 5 Homo sapiens 32-38 25998443-8 2015 Ambroxol suppressed LPS-induced RANTES expression and IL-8 release (p < 0.001), whilst inhibiting iNOS expression (p < 0.05). Ambroxol 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 54-58 25998443-8 2015 Ambroxol suppressed LPS-induced RANTES expression and IL-8 release (p < 0.001), whilst inhibiting iNOS expression (p < 0.05). Ambroxol 0-8 nitric oxide synthase 2 Homo sapiens 101-105 25998443-11 2015 Ambroxol and beclomethasone dipropionate inhibited LPS-stimulated IL-8, MPO and 3-NT release (p < 0.05). Ambroxol 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 66-70 25998443-11 2015 Ambroxol and beclomethasone dipropionate inhibited LPS-stimulated IL-8, MPO and 3-NT release (p < 0.05). Ambroxol 0-8 myeloperoxidase Homo sapiens 72-75 25998443-12 2015 Ambroxol/beclomethasone dipropionate combination potentiated the inhibition of IL-8 and 3-NT production in BEAS-2B with PMNs (p < 0.05 and p < 0.01, respectively). Ambroxol 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 79-89 25998443-14 2015 CONCLUSION: The additive effect of ambroxol and beclomethasone dipropionate on IL-8 and 3-NT inhibition suggests new therapeutic options in the treatment of neutrophil-related respiratory diseases such as chronic obstructive pulmonary disease and respiratory infections. Ambroxol 35-43 C-X-C motif chemokine ligand 8 Homo sapiens 79-89 25174313-6 2014 Treatment with high doses of ambroxol appeared to reduce serum tumor necrosis factor-alpha level (WMD -7.92 microg/L; 95% CI, -10.94 to -4.9) and interleukin-6 level (WMD = -20.65 microg/L, 95% CI: -24.74 to -16.55) and to increase serum superoxide dismutase level (WMD = 19.07 NU/mL, 95% CI: 6.16-31.97). Ambroxol 29-37 interleukin 6 Homo sapiens 146-159 23856970-5 2014 Ambroxol (100 nM) reduced RV14 titers and cytokine concentrations of interleukin (IL)-1beta, IL-6 and IL-8 in the supernatants and RV14 RNA in the cells after RV14 infection, in addition to reducing susceptibility to RV14 infection. Ambroxol 0-8 interleukin 1 beta Homo sapiens 69-91 24998504-5 2014 Moreover, the MUC5AC content in BALF and goblet-cells in large airways of LPS-induced ALI mice were significantly attenuated by dexamethasone (5 mg/kg), ambroxol (25 mg/kg), and naringin (15, 60 mg/kg). Ambroxol 153-161 mucin 5, subtypes A and C, tracheobronchial/gastric Mus musculus 14-20 24574503-15 2014 Ambroxol treatment significantly increases glucosylceramidase activity and reduces markers of oxidative stress in cells bearing glucocerebrosidase mutations. Ambroxol 0-8 glucosylceramidase beta Homo sapiens 43-61 23856970-5 2014 Ambroxol (100 nM) reduced RV14 titers and cytokine concentrations of interleukin (IL)-1beta, IL-6 and IL-8 in the supernatants and RV14 RNA in the cells after RV14 infection, in addition to reducing susceptibility to RV14 infection. Ambroxol 0-8 interleukin 6 Homo sapiens 93-97 23856970-5 2014 Ambroxol (100 nM) reduced RV14 titers and cytokine concentrations of interleukin (IL)-1beta, IL-6 and IL-8 in the supernatants and RV14 RNA in the cells after RV14 infection, in addition to reducing susceptibility to RV14 infection. Ambroxol 0-8 C-X-C motif chemokine ligand 8 Homo sapiens 102-106 23856970-6 2014 Ambroxol also reduced the expression of intercellular adhesion molecule-1 (ICAM-1), the receptor for RV14, and the number of acidic endosomes from which RV14 RNA enters the cytoplasm. Ambroxol 0-8 intercellular adhesion molecule 1 Homo sapiens 40-73 23856970-6 2014 Ambroxol also reduced the expression of intercellular adhesion molecule-1 (ICAM-1), the receptor for RV14, and the number of acidic endosomes from which RV14 RNA enters the cytoplasm. Ambroxol 0-8 intercellular adhesion molecule 1 Homo sapiens 75-81 23856970-7 2014 In addition, ambroxol reduced the activation of the transcription factor nuclear factor kappa B (NF-kappaB) in the nucleus. Ambroxol 13-21 nuclear factor kappa B subunit 1 Homo sapiens 73-95 23856970-7 2014 In addition, ambroxol reduced the activation of the transcription factor nuclear factor kappa B (NF-kappaB) in the nucleus. Ambroxol 13-21 nuclear factor kappa B subunit 1 Homo sapiens 97-106 23856970-8 2014 These results suggest that ambroxol inhibits RV14 infection partly by reducing ICAM-1 and acidic endosomes via the inhibition of NF-kappaB activation. Ambroxol 27-35 intercellular adhesion molecule 1 Homo sapiens 79-85 23856970-8 2014 These results suggest that ambroxol inhibits RV14 infection partly by reducing ICAM-1 and acidic endosomes via the inhibition of NF-kappaB activation. Ambroxol 27-35 nuclear factor kappa B subunit 1 Homo sapiens 129-138 24606981-6 2014 Finally, we analyzed the effects of ambroxol, a Na(v)1.8-preferring blocker on the electrophysiological properties of Nav1.8 currents and on the mechanical sensitivity and inflammation of the hind paw in CFA-treated rats. Ambroxol 36-44 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 118-124 24606981-10 2014 Finally, we found that ambroxol significantly reduces the potentiation of Na(v)1.8 currents in Abeta-fiber neurons observed following intraplantar CFA injection and concomitantly blocks CFA-induced mechanical allodynia, suggesting that Na(v)1.8 regulation in Abeta-fibers contributes to inflammatory pain. Ambroxol 23-31 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 74-82 24606981-10 2014 Finally, we found that ambroxol significantly reduces the potentiation of Na(v)1.8 currents in Abeta-fiber neurons observed following intraplantar CFA injection and concomitantly blocks CFA-induced mechanical allodynia, suggesting that Na(v)1.8 regulation in Abeta-fibers contributes to inflammatory pain. Ambroxol 23-31 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 236-244 24103200-0 2014 A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol. Ambroxol 93-101 peroxiredoxin 5 Homo sapiens 2-23 24103200-0 2014 A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol. Ambroxol 93-101 thioredoxin Homo sapiens 2-13 24103200-3 2014 To address this, we have investigated the effect of ABX on critical antioxidant proteins thioredoxin (Trx) and thioredoxin reductase (TrxR) that are decreased in patients with AECOPD. Ambroxol 52-55 thioredoxin Homo sapiens 89-100 24103200-3 2014 To address this, we have investigated the effect of ABX on critical antioxidant proteins thioredoxin (Trx) and thioredoxin reductase (TrxR) that are decreased in patients with AECOPD. Ambroxol 52-55 thioredoxin Homo sapiens 102-105 24103200-3 2014 To address this, we have investigated the effect of ABX on critical antioxidant proteins thioredoxin (Trx) and thioredoxin reductase (TrxR) that are decreased in patients with AECOPD. Ambroxol 52-55 peroxiredoxin 5 Homo sapiens 111-132 24103200-3 2014 To address this, we have investigated the effect of ABX on critical antioxidant proteins thioredoxin (Trx) and thioredoxin reductase (TrxR) that are decreased in patients with AECOPD. Ambroxol 52-55 peroxiredoxin 5 Homo sapiens 134-138 24103200-5 2014 In human bronchial epithelial cells, treatment with ABX from 0 to 200 muM gradually increased mRNA and protein levels of TrxR/Trx. Ambroxol 52-55 peroxiredoxin 5 Homo sapiens 121-125 24103200-5 2014 In human bronchial epithelial cells, treatment with ABX from 0 to 200 muM gradually increased mRNA and protein levels of TrxR/Trx. Ambroxol 52-55 thioredoxin Homo sapiens 121-124 24103200-6 2014 At these ABX concentrations, TrxR activity was elevated progressively, whereas Trx activity exhibited a dose-dependent biphasic response, increasing at 50 and 75 muM, but decreasing at ABX over 150 muM. Ambroxol 9-12 peroxiredoxin 5 Homo sapiens 29-33 24103200-6 2014 At these ABX concentrations, TrxR activity was elevated progressively, whereas Trx activity exhibited a dose-dependent biphasic response, increasing at 50 and 75 muM, but decreasing at ABX over 150 muM. Ambroxol 9-12 thioredoxin Homo sapiens 29-32 24103200-7 2014 Pre-treatment with 75 muM ABX enhanced the capacity of the cells to eliminate reactive oxygen species, which was largely prevented by knockdown of cytosolic Trx (hTrx1). Ambroxol 26-29 thioredoxin Homo sapiens 157-160 24103200-7 2014 Pre-treatment with 75 muM ABX enhanced the capacity of the cells to eliminate reactive oxygen species, which was largely prevented by knockdown of cytosolic Trx (hTrx1). Ambroxol 26-29 thioredoxin Homo sapiens 162-167 24103200-8 2014 In a purified system, ABX shortened the initial lag phase during the reduction of insulin disulfide by Trx system. Ambroxol 22-25 thioredoxin Homo sapiens 103-106 24103200-9 2014 Pre-treatment of NADPH-reduced TrxR with ABX caused a dose- and time-dependent increase in thiolate/selenolate species, i.e. the catalytically active form of TrxR. Ambroxol 41-44 peroxiredoxin 5 Homo sapiens 31-35 24103200-9 2014 Pre-treatment of NADPH-reduced TrxR with ABX caused a dose- and time-dependent increase in thiolate/selenolate species, i.e. the catalytically active form of TrxR. Ambroxol 41-44 peroxiredoxin 5 Homo sapiens 158-162 24103200-10 2014 Kinetic analysis demonstrated that the reduction of H2O2 by TrxR or Trx system were enhanced by 100 or 200 muM ABX. Ambroxol 111-114 peroxiredoxin 5 Homo sapiens 60-64 24103200-10 2014 Kinetic analysis demonstrated that the reduction of H2O2 by TrxR or Trx system were enhanced by 100 or 200 muM ABX. Ambroxol 111-114 thioredoxin Homo sapiens 60-63 24103200-11 2014 When hTrx1 was mixed with ABX in a molar ratio of 1:1 to 1:100 (which could occur in human plasma), changes in intrinsic Trp fluorescence occurred, and the response of reduced hTrx1 was especially remarkable. Ambroxol 26-29 thioredoxin Homo sapiens 176-181 24103200-12 2014 These data reveal an ABX-sensing mechanism of TrxR/Trx. Ambroxol 21-24 peroxiredoxin 5 Homo sapiens 46-50 24103200-12 2014 These data reveal an ABX-sensing mechanism of TrxR/Trx. Ambroxol 21-24 thioredoxin Homo sapiens 46-49 24103200-13 2014 We therefore conclude that the antioxidant actions of ABX at physiological concentrations are, at least partially, mediated by TrxR and/or Trx system. Ambroxol 54-57 peroxiredoxin 5 Homo sapiens 127-131 24103200-13 2014 We therefore conclude that the antioxidant actions of ABX at physiological concentrations are, at least partially, mediated by TrxR and/or Trx system. Ambroxol 54-57 thioredoxin Homo sapiens 127-130 23765701-3 2013 In cells expressing wt-CFTR, ambroxol increased the Cl(-) conductance, but not the bicarbonate conductance of the CFTR channels. Ambroxol 29-37 CF transmembrane conductance regulator Homo sapiens 23-27 23765701-5 2013 CFBE cells were treated with 100 microM ambroxol for 2, 4 or 8 h. mRNA expression for CFTR and ENaC subunits was analysed by real-time polymerase chain reaction (RT-PCR); protein expression was measured by Western blot. Ambroxol 40-48 CF transmembrane conductance regulator Homo sapiens 86-90 23765701-7 2013 Ambroxol significantly stimulated Cl(-) efflux from CFBE cells (a sixfold increase after 8 h treatment), and enhanced the expression of the mRNA of CFTR and alpha-ENaC, and of the CFTR protein. Ambroxol 0-8 CF transmembrane conductance regulator Homo sapiens 180-184 23765701-7 2013 Ambroxol significantly stimulated Cl(-) efflux from CFBE cells (a sixfold increase after 8 h treatment), and enhanced the expression of the mRNA of CFTR and alpha-ENaC, and of the CFTR protein. Ambroxol 0-8 CF transmembrane conductance regulator Homo sapiens 148-152 23765701-11 2013 Upregulation of CFTR and enhanced Cl(-) efflux after ambroxol treatment should promote transepithelial ion and water transport, which may improve hydration of the mucus, and therefore be beneficial to CF-patients. Ambroxol 53-61 CF transmembrane conductance regulator Homo sapiens 16-20 23765701-7 2013 Ambroxol significantly stimulated Cl(-) efflux from CFBE cells (a sixfold increase after 8 h treatment), and enhanced the expression of the mRNA of CFTR and alpha-ENaC, and of the CFTR protein. Ambroxol 0-8 sodium channel epithelial 1 subunit alpha Homo sapiens 157-167 23113953-0 2012 Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells. Ambroxol 46-54 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 58-64 24355223-1 2013 The purpose of the present study was to investigate the possible anti-oxidant effect(s) of Ambroxol on neutrophils activated by ligand-binding of the drug with membrane-associated adhesion integrin CD11a and to estimate dose-response changes in oxygen free radical production. Ambroxol 91-99 integrin subunit alpha L Homo sapiens 198-203 24355223-3 2013 A significant dose-dependent effect response of Ambroxol on O2&#8254; production by cells coated with anti-CD11a antibody was observed. Ambroxol 48-56 integrin subunit alpha L Homo sapiens 111-116 23158495-7 2013 Here we show that ambroxol increases both the lysosomal fraction and the enzymatic activity of several mutant GCase variants in skin fibroblasts derived from Type 1 and Type 2 GD patients. Ambroxol 18-26 glucosylceramidase beta Homo sapiens 110-115 23953561-12 2013 Use of ambroxol reduced the histologic injury and significantly decreased serum ALT and AST levels. Ambroxol 7-15 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 88-91 23953561-13 2013 In addition, ambroxol enhanced the activity of hepatic tissue SOD and CAT, increasing GSH but decreasing MDA tissue contents. Ambroxol 13-21 catalase Rattus norvegicus 70-73 23953561-15 2013 Furthermore, ambroxol reduced levels of phosphorylated JNK (P < .05). Ambroxol 13-21 mitogen-activated protein kinase 8 Rattus norvegicus 55-58 23113953-3 2012 We examined the effects of guaifenesin (GGE), N-acetylcysteine (NAC) and ambroxol (Amb) on differentiated human airway epithelial cells stimulated with IL-13 to produce additional MUC5AC. Ambroxol 83-86 interleukin 13 Homo sapiens 152-157 21714251-0 2011 [Interaction between ambroxol hydrochloride and human serum albumin studied by spectroscopic and molecular modeling methods]. Ambroxol 21-43 albumin Homo sapiens 54-67 23325993-0 2012 Enhanced Controlled Transdermal Delivery of Ambroxol from the EVA Matrix. Ambroxol 44-52 myelin protein zero-like 2 Rattus norvegicus 62-65 23325993-7 2012 To increase the permeation rate of ambroxol across rat skin from the EVA matrix, various penetration enhancers such as fatty acids (saturated, unsaturated), propylene glycols, glycerides, pyrrolidones, and non-ionic surfactants were used. Ambroxol 35-43 myelin protein zero-like 2 Rattus norvegicus 69-72 23325993-10 2012 In conclusion, EVA matrix containing plasticizer and permeation enhancer could be developed for enhanced transdermal delivery of ambroxol. Ambroxol 129-137 myelin protein zero-like 2 Rattus norvegicus 15-18 22127815-4 2012 METHODS: The Nav1.8 blockers, A-803467 or ambroxol, were injected intrathecally either before or after intraplantar capsaicin injection. Ambroxol 42-50 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 13-19 21845882-0 2011 [Effects of ambroxol combined with low-dose heparin on TNF-alpha and IL-1beta in rabbits with acute lung injury]. Ambroxol 12-20 tumor necrosis factor Oryctolagus cuniculus 55-64 21845882-0 2011 [Effects of ambroxol combined with low-dose heparin on TNF-alpha and IL-1beta in rabbits with acute lung injury]. Ambroxol 12-20 interleukin-1 beta Oryctolagus cuniculus 69-77 21845882-1 2011 OBJECTIVE: To investigate the intervention and mechanism of ambroxol combined with low-dose heparin on oxidative stress, TNF-alpha and IL-1beta in rabbits with acute lung injury (ALI). Ambroxol 60-68 tumor necrosis factor Oryctolagus cuniculus 121-130 21845882-1 2011 OBJECTIVE: To investigate the intervention and mechanism of ambroxol combined with low-dose heparin on oxidative stress, TNF-alpha and IL-1beta in rabbits with acute lung injury (ALI). Ambroxol 60-68 interleukin-1 beta Oryctolagus cuniculus 135-143 21845882-16 2011 Ambroxol combined with low-dose heparin can reduce lung cells oxidative stress to inhibit the release of IL-1beta and TNF-alpha, which play a role in the treatment of ALI. Ambroxol 0-8 interleukin-1 beta Oryctolagus cuniculus 105-113 21845882-16 2011 Ambroxol combined with low-dose heparin can reduce lung cells oxidative stress to inhibit the release of IL-1beta and TNF-alpha, which play a role in the treatment of ALI. Ambroxol 0-8 tumor necrosis factor Oryctolagus cuniculus 118-127 21714251-1 2011 In the present paper, the interaction between ambroxol hydrochloride (ABX) and human serum albumin (HSA) was studied under simulative physiological condition by spectroscopy and molecular modeling method. Ambroxol 46-68 albumin Homo sapiens 85-98 21714251-1 2011 In the present paper, the interaction between ambroxol hydrochloride (ABX) and human serum albumin (HSA) was studied under simulative physiological condition by spectroscopy and molecular modeling method. Ambroxol 70-73 albumin Homo sapiens 85-98 21454975-11 2011 The cytokine responses, namely the level of IFN-gamma and the ratio of IFN-gamma and IL-10, were also reduced with the effect of ambroxol. Ambroxol 129-137 interferon gamma Rattus norvegicus 44-53 21454975-11 2011 The cytokine responses, namely the level of IFN-gamma and the ratio of IFN-gamma and IL-10, were also reduced with the effect of ambroxol. Ambroxol 129-137 interferon gamma Rattus norvegicus 71-80 21454975-11 2011 The cytokine responses, namely the level of IFN-gamma and the ratio of IFN-gamma and IL-10, were also reduced with the effect of ambroxol. Ambroxol 129-137 interleukin 10 Rattus norvegicus 85-90 20732348-4 2010 Ambroxol has previously demonstrated antinociceptive effects in rat chronic pain models and has also shown to potently block Na(+) channel current in DRG neurons. Ambroxol 0-8 sodium voltage-gated channel alpha subunit 8 Rattus norvegicus 125-138 19636975-7 2010 Radiotherapy-induced elevation of TNF-alpha levels, seen in control patients, was also abolished after treatment with ambroxol (5.1 +/- 1.0 vs. 2.4 +/- 0.8 ng/ml, P < 0.001). Ambroxol 118-126 tumor necrosis factor Homo sapiens 34-43 19636975-9 2010 Ambroxol decreased the expression of TGF-beta(1) and TNF-alpha, and minimized the diminishment of lung diffusion capacity after radiotherapy. Ambroxol 0-8 transforming growth factor beta 1 Homo sapiens 37-48 19636975-0 2010 The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor beta1 and tumor necrosis factor alpha. Ambroxol 26-34 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 118-155 19636975-9 2010 Ambroxol decreased the expression of TGF-beta(1) and TNF-alpha, and minimized the diminishment of lung diffusion capacity after radiotherapy. Ambroxol 0-8 tumor necrosis factor Homo sapiens 53-62 18696263-7 2009 Pretreatment of the immobilized mucin with ambroxol, bromhexine, ammonium chloride, or ammonium acetate reduced the adherence of Pseudomonas aeruginosa, Escherichia coli, and staphylococcal isolates to this receptor analogue. Ambroxol 43-51 LOC100508689 Homo sapiens 32-37 20044988-3 2010 With properties resembling those of local anesthetics, ambroxol has been reported to block Na(+) currents in sensory neurons with a preference for tetrodotoxin-resistant (TTXr) Na(+) currents encoded by Na(v)1.8. Ambroxol 55-63 sodium voltage-gated channel alpha subunit 10 Homo sapiens 203-211 20044988-6 2010 Tonic and use-dependent block by ambroxol was strongly alleviated in local anesthetic-insensitive Na(v)1.4 mutants. Ambroxol 33-41 immunoglobulin lambda variable 2-14 Homo sapiens 98-106 20044988-8 2010 The TTXs subunit Na(v)1.3 displayed the least degree of use-dependent block by ambroxol. Ambroxol 79-87 immunoglobulin lambda variable 2-11 Homo sapiens 17-25 20044988-13 2010 Ambroxol preferentially blocks Na(v)1.8, however shares this property with established local anesthetics like mepivacaine. Ambroxol 0-8 sodium voltage-gated channel alpha subunit 10 Homo sapiens 31-39 20074455-7 2009 Ambroxol was also more potent than either sputolysin or vasicine in attenuating basophil IL-4 and IL-13 secretions, whereas bromhexine-induced suppression of de novo cytokine synthesis was due to toxic effects. Ambroxol 0-8 interleukin 4 Homo sapiens 89-93 20074455-7 2009 Ambroxol was also more potent than either sputolysin or vasicine in attenuating basophil IL-4 and IL-13 secretions, whereas bromhexine-induced suppression of de novo cytokine synthesis was due to toxic effects. Ambroxol 0-8 interleukin 13 Homo sapiens 98-103 20074455-8 2009 Additionally, ambroxol reduced IgE-dependent p38 MAPK phosphorylation in basophils, unlike bromhexine, sputolysin and vasicine. Ambroxol 14-22 mitogen-activated protein kinase 14 Homo sapiens 45-48 20074455-9 2009 These results clearly show that ambroxol is both more potent and effective at inhibiting IgE-dependent basophil mediator release and p38 MAPK activity than the other secretolytic analogues employed. Ambroxol 32-40 mitogen-activated protein kinase 14 Homo sapiens 133-136 18280225-0 2008 Upregulation of AQP3 and AQP5 induced by dexamethasone and ambroxol in A549 cells. Ambroxol 59-67 aquaporin 3 (Gill blood group) Homo sapiens 16-20 18664347-11 2008 The change of IL-8 level before and after treatment in Tanreqing group was greater than that in ambroxol hydrochloride group and the control group. Ambroxol 96-118 C-X-C motif chemokine ligand 8 Homo sapiens 14-18 18664347-12 2008 The changes of IL-10 and NE levels in ambroxol hydrochloride group were greater than those in Tanreqing group and the control group, while there was no significant difference in the changes of serum levels of IL-8, IL-10 and NE among the three groups (P>0.05). Ambroxol 38-60 interleukin 10 Homo sapiens 15-20 18664347-12 2008 The changes of IL-10 and NE levels in ambroxol hydrochloride group were greater than those in Tanreqing group and the control group, while there was no significant difference in the changes of serum levels of IL-8, IL-10 and NE among the three groups (P>0.05). Ambroxol 38-60 elastase, neutrophil expressed Homo sapiens 25-27 18280225-7 2008 Both dexamethasone and ambroxol stimulated the expression of AQP3 and 5 at the mRNA and protein levels. Ambroxol 23-31 aquaporin 3 (Gill blood group) Homo sapiens 61-71 18280225-0 2008 Upregulation of AQP3 and AQP5 induced by dexamethasone and ambroxol in A549 cells. Ambroxol 59-67 aquaporin 5 Homo sapiens 25-29 16546120-4 2006 Ambroxol of 100 microM diminished the terbutaline (a beta2-adrenergic agonist)-stimulated Cl-/HCO3(-)-dependent secretion without any decreases in the conductance of cystic fibrosis transmembrane conductance regulator (CFTR) channel locating on the apical membrane. Ambroxol 0-8 CF transmembrane conductance regulator Homo sapiens 219-223 19137906-6 2008 Presently, the evidence from randomised, placebo-controlled, double-blind clinical trials (RCT) with the local anaesthetic ambroxol (CAS 23828-92-4) in the treatment of sore throat is being reviewed. Ambroxol 123-131 BCAR1 scaffold protein, Cas family member Homo sapiens 133-136 17311557-10 2007 The combination of neuraminidase inhibitors and protease inhibitors, clarithromycin or ambroxol, could be potentially used as a potent anti-influenza therapy to minimize the emergence of drug-resistant mutant viruses. Ambroxol 87-95 neuraminidase 1 Homo sapiens 19-32 16546120-5 2006 On the other hand, under the basal (unstimulated) condition ambroxol increased the Cl(-)-dependent secretion with no significant change in the apical CFTR channel conductance and decreased the HCO3- secretion associated with a decrease in the apical CFTR channel conductance. Ambroxol 60-68 CF transmembrane conductance regulator Homo sapiens 250-254 15576322-7 2004 One of these compounds, ambroxol, is a mucolytic and anti-oxidant agent that stimulates the release of secretory leukoprotease inhibitor and pulmonary surfactant in the early phase, and IgA in the late phase of infection at an optimal dose, i.e. a dose sufficient to inhibit virus proliferation and increase the survival rate of animals after treatment with a lethal dose of IAV. Ambroxol 24-32 CD79a molecule Homo sapiens 186-189 16459489-3 2005 The study aimed to estimate the influence of ambroxol (ABX) and capsaicin (CAPSA) on PD and dPD in isolated rabbit bladder. Ambroxol 45-53 dachs Drosophila melanogaster 85-87 16459489-3 2005 The study aimed to estimate the influence of ambroxol (ABX) and capsaicin (CAPSA) on PD and dPD in isolated rabbit bladder. Ambroxol 55-58 dachs Drosophila melanogaster 85-87 15694461-7 2005 However, ambroxol treatment resulted in a significant increase of SP-B and in a decrease of SP-D in whole lung tissue with enhanced immunostaining for SP-B in Clara Cells. Ambroxol 9-17 surfactant protein D Rattus norvegicus 92-96 15694461-7 2005 However, ambroxol treatment resulted in a significant increase of SP-B and in a decrease of SP-D in whole lung tissue with enhanced immunostaining for SP-B in Clara Cells. Ambroxol 9-17 surfactant protein B Rattus norvegicus 151-155 15694461-8 2005 SP-A and SP-D were significantly decreased in BAL fluid of ambroxol-treated animals. Ambroxol 59-67 surfactant protein A1 Rattus norvegicus 0-4 15694461-8 2005 SP-A and SP-D were significantly decreased in BAL fluid of ambroxol-treated animals. Ambroxol 59-67 surfactant protein D Rattus norvegicus 9-13 16182323-0 2005 Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Ambroxol 0-8 sodium voltage-gated channel alpha subunit 10 Homo sapiens 12-18 16182323-4 2005 Recently, the secretolytic ambroxol was found to preferentially inhibit Nav1.8 channels. Ambroxol 27-35 sodium voltage-gated channel alpha subunit 10 Homo sapiens 72-78 15694461-6 2005 In isolated type II pneumocytes of ambroxol-treated animals, SP-C protein and mRNA content were increased, whereas SP-A, -B and -D protein, mRNA, and immunoreactivity remained unaffected. Ambroxol 35-43 surfactant protein C Rattus norvegicus 61-65 15694461-6 2005 In isolated type II pneumocytes of ambroxol-treated animals, SP-C protein and mRNA content were increased, whereas SP-A, -B and -D protein, mRNA, and immunoreactivity remained unaffected. Ambroxol 35-43 surfactant protein A1 Rattus norvegicus 115-130 15694461-7 2005 However, ambroxol treatment resulted in a significant increase of SP-B and in a decrease of SP-D in whole lung tissue with enhanced immunostaining for SP-B in Clara Cells. Ambroxol 9-17 surfactant protein B Rattus norvegicus 66-70 14505809-4 2003 Ambroxol (10-100 microM) reduced the 75 mU/mL BLM-induced cell death and activation of caspase-3 in macrophages or epithelial cells. Ambroxol 0-8 caspase 3 Homo sapiens 87-96 14504727-8 2004 Compared to the control group, TNF-alpha, IL-6 and TGF-beta1 levels in the BAL in both ambroxol- and dexamethasone-treated groups were significantly reduced at 24 and 48 h. The protein in BAL, an index of vascular permeability, was also significantly decreased in the ambroxol- and dexamethasone-treated groups (p<0.05). Ambroxol 87-95 tumor necrosis factor Mus musculus 31-40 14504727-8 2004 Compared to the control group, TNF-alpha, IL-6 and TGF-beta1 levels in the BAL in both ambroxol- and dexamethasone-treated groups were significantly reduced at 24 and 48 h. The protein in BAL, an index of vascular permeability, was also significantly decreased in the ambroxol- and dexamethasone-treated groups (p<0.05). Ambroxol 87-95 interleukin 6 Mus musculus 42-46 14504727-8 2004 Compared to the control group, TNF-alpha, IL-6 and TGF-beta1 levels in the BAL in both ambroxol- and dexamethasone-treated groups were significantly reduced at 24 and 48 h. The protein in BAL, an index of vascular permeability, was also significantly decreased in the ambroxol- and dexamethasone-treated groups (p<0.05). Ambroxol 87-95 transforming growth factor, beta 1 Mus musculus 51-60 15265434-1 2004 OBJECTIVE: To investigate the effects of maternally administered dexamethasone and ambroxol on the mRNA levels of surfactant proteins (SP-A, SP-B and SP-C) expression in fetal rat lungs at gestational age day 19. Ambroxol 83-91 surfactant protein A1 Rattus norvegicus 135-139 15265434-1 2004 OBJECTIVE: To investigate the effects of maternally administered dexamethasone and ambroxol on the mRNA levels of surfactant proteins (SP-A, SP-B and SP-C) expression in fetal rat lungs at gestational age day 19. Ambroxol 83-91 surfactant protein C Rattus norvegicus 150-154 15265434-8 2004 CONCLUSION: Antepartum administration of both ambroxol and dexamethasone can significantly increase fetal lung SP-A, SP-B and SP-C mRNAs expression. Ambroxol 46-54 surfactant protein A1 Rattus norvegicus 111-115 15265434-8 2004 CONCLUSION: Antepartum administration of both ambroxol and dexamethasone can significantly increase fetal lung SP-A, SP-B and SP-C mRNAs expression. Ambroxol 46-54 surfactant protein B Rattus norvegicus 117-121 15265434-8 2004 CONCLUSION: Antepartum administration of both ambroxol and dexamethasone can significantly increase fetal lung SP-A, SP-B and SP-C mRNAs expression. Ambroxol 46-54 surfactant protein C Rattus norvegicus 126-130 14534155-3 2003 This study was planned in order to investigate if ambroxol and its precursor bromhexine are actually capable of preventing alpha-1-antitrypsin (A1AT) inactivation by stimulated neutrophils and possibly to look into the mechanisms underlying this event. Ambroxol 50-58 serpin family A member 1 Homo sapiens 123-142 14534155-3 2003 This study was planned in order to investigate if ambroxol and its precursor bromhexine are actually capable of preventing alpha-1-antitrypsin (A1AT) inactivation by stimulated neutrophils and possibly to look into the mechanisms underlying this event. Ambroxol 50-58 serpin family A member 1 Homo sapiens 144-148 14534155-7 2003 Ambroxol decreased the release of elastase and myeloperoxidase from activated neutrophils, whereas bromhexine was ineffective. Ambroxol 0-8 myeloperoxidase Homo sapiens 47-62 12030738-6 2002 In addition, ambroxol transiently suppressed release of the cytokines, tumour necrosis factor-alpha, interferon-gamma and interleukin-12, into airway fluid. Ambroxol 13-21 interferon gamma Mus musculus 101-117 14534155-8 2003 Ambroxol prevented the A1AT inactivation by neutrophils, whereas bromhexine was completely ineffective. Ambroxol 0-8 serpin family A member 1 Homo sapiens 23-27 14534155-9 2003 Among drugs currently available for in vivo use in humans, ambroxol is unique by virtue of its ability to prevent neutrophil-mediated A1AT inactivation via inhibition of HOCl production as well as HOCl scavenging. Ambroxol 59-67 serpin family A member 1 Homo sapiens 134-138 12753420-2 2003 Ambroxol and erdosteine significantly decreased the production of tumour necrosis factors-alpha, interleukin-1beta, and interleukin-6 in alveolar macrophages activated by lipopolysaccharide. Ambroxol 0-8 interleukin 1 beta Rattus norvegicus 97-114 12753420-2 2003 Ambroxol and erdosteine significantly decreased the production of tumour necrosis factors-alpha, interleukin-1beta, and interleukin-6 in alveolar macrophages activated by lipopolysaccharide. Ambroxol 0-8 interleukin 6 Rattus norvegicus 120-133 12427115-0 2002 Ambroxol inhibits peroxynitrite-induced damage of alpha1-antiproteinase and free radical production in activated phagocytic cells. Ambroxol 0-8 serpin family A member 1 Homo sapiens 50-71 12427115-2 2002 Ambroxol decreased the inactivation or destruction of alpha1-antiproteinase induced by peroxynitrite (ONOO-) or hypochlorous acid (HOCl), which was similar to penicillamine and glutathione and was greater than diclofenac sodium and naproxen sodium. Ambroxol 0-8 serpin family A member 1 Homo sapiens 54-75 12427115-4 2002 Ambroxol significantly attenuated the production of superoxide, hydrogen peroxide, HOCl, and nitric oxide in fMLP- or IL-1-activated phagocytic cells, while the inhibitory effects of antiinflammatory and thiol compounds were only observed in HOCl production. Ambroxol 0-8 formyl peptide receptor 1 Homo sapiens 109-113 12427115-4 2002 Ambroxol significantly attenuated the production of superoxide, hydrogen peroxide, HOCl, and nitric oxide in fMLP- or IL-1-activated phagocytic cells, while the inhibitory effects of antiinflammatory and thiol compounds were only observed in HOCl production. Ambroxol 0-8 interleukin 1 alpha Homo sapiens 118-122 12427115-7 2002 Ambroxol may interfere with oxidative damage of alpha1-antiproteinase through a scavenging action on ONOO- and HOCl and inhibition of the respiratory burst of phagocytic cells. Ambroxol 0-8 serpin family A member 1 Homo sapiens 48-69 12070428-2 2002 The experiments permitted to analyze an effect of ambroxol on regulatory mechanisms, which in turn influence the constant electrical potential defined as PD and reversible changes of this potential during mechanical stimulation (marked as dPD). Ambroxol 50-58 dachs Drosophila melanogaster 239-242 12070428-6 2002 RESULTS: It has been demonstrated that ambroxol influences the processes of ion transport (dPD) which in turn depend on mechanical stimulation. Ambroxol 39-47 dachs Drosophila melanogaster 91-94 11963647-4 2002 OBJECTIVE: Description and comparison of the efficacy and tolerability of lozenges containing 20 mg ambroxol hydrochloride (trans-4-[(2-amino-3,5-dibrombenzyl)amino]cyclohexano hydrochloride, CAS 18683-91-5) in relieving acute sore throat, in comparison to placebo. Ambroxol 100-122 BCAR1 scaffold protein, Cas family member Homo sapiens 192-195 11834245-2 2002 We investigated the effect of ambroxol, trans-4-[(2-amino-3,5-dibromobenzyl) amino] cyclohexanol hydrochloride, on the lipopolysaccharide-induced PDGF production in human monocytic cells, THP-1. Ambroxol 30-38 GLI family zinc finger 2 Homo sapiens 188-193 11834245-3 2002 Ambroxol inhibited the lipopolysaccharide-induced PDGF-AB production via PDGF-A mRNA expression. Ambroxol 0-8 platelet derived growth factor subunit A Homo sapiens 50-56 11834245-4 2002 Lipopolysaccharide activated p44/42 extracellular signal-regulated kinase (ERK), and ambroxol attenuated the lipopolysaccharide-induced p44/42 ERK activation. Ambroxol 85-93 interferon induced protein 44 Homo sapiens 136-139 11834245-4 2002 Lipopolysaccharide activated p44/42 extracellular signal-regulated kinase (ERK), and ambroxol attenuated the lipopolysaccharide-induced p44/42 ERK activation. Ambroxol 85-93 mitogen-activated protein kinase 1 Homo sapiens 143-146 11834245-6 2002 These findings indicate that ambroxol inhibits the lipopolysaccharide-induced PDGF production due to the suppression of p44/42 ERK activity. Ambroxol 29-37 interferon induced protein 44 Homo sapiens 120-123 11834245-6 2002 These findings indicate that ambroxol inhibits the lipopolysaccharide-induced PDGF production due to the suppression of p44/42 ERK activity. Ambroxol 29-37 mitogen-activated protein kinase 1 Homo sapiens 127-130 11805226-2 2002 The action of ambroxol was assayed by measuring changes in the activities of protein kinase C (PKC) and tyrosine kinase (PTK) and in the intracellular calcium level. Ambroxol 14-22 protein kinase C, gamma Rattus norvegicus 77-93 11805226-2 2002 The action of ambroxol was assayed by measuring changes in the activities of protein kinase C (PKC) and tyrosine kinase (PTK) and in the intracellular calcium level. Ambroxol 14-22 protein kinase C, gamma Rattus norvegicus 95-98 11124650-0 2000 Effects of N-acetylcysteine and ambroxol on the production of IL-12 and IL-10 in human alveolar macrophages. Ambroxol 32-40 interleukin 10 Homo sapiens 72-77 10887941-3 2000 The application of ACE inhibitors into culture media containing BAL cells inhibited spontaneous and stimulated generation of ROS by BAL cells from COPD patients and control subjects in an ambroxol-concentration-dependent manner. Ambroxol 188-196 angiotensin I converting enzyme Homo sapiens 19-22 10845438-1 2000 In a randomized trial in 102 preterm newborns with respiratory distress syndrome (RDS) it has been shown that early Ambroxol treatment (30 mg kg(-1) over the first 5 days) significantly reduces the incidence of RDS-associated complications [bronchopulmonary dysplasia (BPD), intraventricular haemorrhage, post-natal acquired pneumonia]. Ambroxol 116-124 peripherin 2 Homo sapiens 82-85 10845438-1 2000 In a randomized trial in 102 preterm newborns with respiratory distress syndrome (RDS) it has been shown that early Ambroxol treatment (30 mg kg(-1) over the first 5 days) significantly reduces the incidence of RDS-associated complications [bronchopulmonary dysplasia (BPD), intraventricular haemorrhage, post-natal acquired pneumonia]. Ambroxol 116-124 peripherin 2 Homo sapiens 211-214 11124650-4 2000 OBJECTIVE: We investigated the effects of NAC and AMB on secretions of IL-12 and IL-10 from human alveolar macrophages. Ambroxol 50-53 interleukin 10 Homo sapiens 81-86 11798737-8 2000 Ambroxol could significantly decrease the locally produced TNF-alpha and inhibit the oxidative reactions, and increase the locally antioxidative potency. Ambroxol 0-8 tumor necrosis factor Rattus norvegicus 59-68 10659952-0 2000 Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes. Ambroxol 86-94 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 18-24 10659952-8 2000 Of the recombinant CYP examined, only CYP3A4 metabolized ambroxol to DBAA. Ambroxol 57-65 peptidylprolyl isomerase G Homo sapiens 19-22 10659952-8 2000 Of the recombinant CYP examined, only CYP3A4 metabolized ambroxol to DBAA. Ambroxol 57-65 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 38-44 10659952-13 2000 These results suggest that CYP3A4 is predominantly involved in the metabolism of ambroxol to DBAA in humans. Ambroxol 81-89 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 27-33 10202994-8 1999 Ambroxol (100 microM) strikingly inhibited anti-IgE induced release of both histamine, LTC4, IL-4 and IL-13 from basophils and reduced both histamine and LTB4 release induced by C5a or Zymosan in monocytes. Ambroxol 0-8 interleukin 4 Homo sapiens 93-97 10556685-1 1999 Ambroxol (100 microM and 1 mM) and the thiols (all 1 mM), glutathione, tiopronin and cysteine, significantly attenuated the myeloperoxidase, H(2)O(2) and Cl(-) system-caused destruction of alpha(1)-antiproteinase and the HOCl-induced destruction of collagen, whereas they did not affect the elastase-induced destruction of collagen. Ambroxol 0-8 myeloperoxidase Homo sapiens 124-139 10556685-1 1999 Ambroxol (100 microM and 1 mM) and the thiols (all 1 mM), glutathione, tiopronin and cysteine, significantly attenuated the myeloperoxidase, H(2)O(2) and Cl(-) system-caused destruction of alpha(1)-antiproteinase and the HOCl-induced destruction of collagen, whereas they did not affect the elastase-induced destruction of collagen. Ambroxol 0-8 serpin family A member 1 Homo sapiens 189-212 10556685-6 1999 The results show that ambroxol may interfere with oxidative tissue damage and decrease proteolytic tissue destruction by attenuation of oxidative stress-induced inactivation of alpha(1)-antiproteinase through both decomposition of HOCl and inhibition of the respiratory burst in phagocytic cells. Ambroxol 22-30 serpin family A member 1 Homo sapiens 177-200 10068151-4 1999 Ambroxol decreased the release of myeloperoxidase and lysozyme evoked by 0.5 mg/ml degraded immunoglobulin G and 1 microM fMLP in a dose-dependent fashion, and at the concentration of 100 microM, 37.1% to 64.2% of inhibitions were observed. Ambroxol 0-8 myeloperoxidase Mus musculus 34-49 10068151-5 1999 The stimulatory effect of phorbol 12-myristate 13-acetate (PMA) (0.1 microg/ml) on superoxide production and myeloperoxidase, which is inhibited by 100 nM staurosporine, was not affected by 100 microM ambroxol. Ambroxol 201-209 myeloperoxidase Mus musculus 109-124 10202994-8 1999 Ambroxol (100 microM) strikingly inhibited anti-IgE induced release of both histamine, LTC4, IL-4 and IL-13 from basophils and reduced both histamine and LTB4 release induced by C5a or Zymosan in monocytes. Ambroxol 0-8 interleukin 13 Homo sapiens 102-107 10202994-8 1999 Ambroxol (100 microM) strikingly inhibited anti-IgE induced release of both histamine, LTC4, IL-4 and IL-13 from basophils and reduced both histamine and LTB4 release induced by C5a or Zymosan in monocytes. Ambroxol 0-8 complement C5a receptor 1 Homo sapiens 178-181 9089888-10 1997 NAC and GSH had no anti-O-2 function, while ambroxol (10(-4) mol/l) reduced O-2 by 14.3 +/- 6.7%. Ambroxol 44-52 immunoglobulin kappa variable 1D-39 Homo sapiens 76-79 8831801-4 1996 The reaction constants of hydroxyl radicals with bromhexine and ambroxol were determined by competition kinetics to be 1.58 +/- 0.15 x 10(10) M-1S-1 and 1.04 +/- 0.1 x 10(10) M-1S-1, respectively. Ambroxol 64-72 tumor associated calcium signal transducer 2 Homo sapiens 142-154 8831801-4 1996 The reaction constants of hydroxyl radicals with bromhexine and ambroxol were determined by competition kinetics to be 1.58 +/- 0.15 x 10(10) M-1S-1 and 1.04 +/- 0.1 x 10(10) M-1S-1, respectively. Ambroxol 64-72 tumor associated calcium signal transducer 2 Homo sapiens 142-148 8119565-8 1993 Inducing prepartually lung-maturity with glucocorticoides or ambroxol resulted in a significant decrease of the RDS-rate in new born children up to the 34th week of gestation. Ambroxol 61-69 peripherin 2 Homo sapiens 112-115 35487151-0 2022 Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2. Ambroxol 24-32 surface glycoprotein Severe acute respiratory syndrome coronavirus 2 126-131 34940303-10 2021 The level of caspase-3 was the highest in the ABX-NS-released particle-treated samples, with a value of 416.6 +- 9.11 pg/mL. Ambroxol 46-49 caspase 3 Homo sapiens 13-22 34940303-11 2021 Meanwhile, the levels of nuclear factor kappa beta, interleukins 6 and 1 beta, and tumour necrosis alpha (NF-kB, IL-6, IL-1beta, and TNF-alpha, respectively) were lower for ABX-NS compared to free ABX (p < 0.05). Ambroxol 173-176 interleukin 6 Homo sapiens 52-77 34940303-11 2021 Meanwhile, the levels of nuclear factor kappa beta, interleukins 6 and 1 beta, and tumour necrosis alpha (NF-kB, IL-6, IL-1beta, and TNF-alpha, respectively) were lower for ABX-NS compared to free ABX (p < 0.05). Ambroxol 173-176 interleukin 6 Homo sapiens 113-117 34940303-11 2021 Meanwhile, the levels of nuclear factor kappa beta, interleukins 6 and 1 beta, and tumour necrosis alpha (NF-kB, IL-6, IL-1beta, and TNF-alpha, respectively) were lower for ABX-NS compared to free ABX (p < 0.05). Ambroxol 173-176 interleukin 1 alpha Homo sapiens 119-127 34940303-11 2021 Meanwhile, the levels of nuclear factor kappa beta, interleukins 6 and 1 beta, and tumour necrosis alpha (NF-kB, IL-6, IL-1beta, and TNF-alpha, respectively) were lower for ABX-NS compared to free ABX (p < 0.05). Ambroxol 173-176 tumor necrosis factor Homo sapiens 133-142 34940303-11 2021 Meanwhile, the levels of nuclear factor kappa beta, interleukins 6 and 1 beta, and tumour necrosis alpha (NF-kB, IL-6, IL-1beta, and TNF-alpha, respectively) were lower for ABX-NS compared to free ABX (p < 0.05). Ambroxol 197-200 interleukin 6 Homo sapiens 52-77 2085143-1 1990 We have studied the effect of Ambroxol on the production of Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) in human mononuclear cells (MNC). Ambroxol 30-38 tumor necrosis factor Homo sapiens 85-106 2085143-1 1990 We have studied the effect of Ambroxol on the production of Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) in human mononuclear cells (MNC). Ambroxol 30-38 tumor necrosis factor Homo sapiens 108-111 2085143-3 1990 The results indicate that Ambroxol markedly inhibited IL-1 and TNF production at doses of 10-100 microgram ml, without any apparent toxicity. Ambroxol 26-34 tumor necrosis factor Homo sapiens 63-66 34817700-11 2021 Additionally, IL-1beta and TNF-alpha were upregulated on Ambroxol-PEG in relation to Control at 07 days (p < 0.05). Ambroxol 57-65 interleukin 1 alpha Rattus norvegicus 14-22 34817700-11 2021 Additionally, IL-1beta and TNF-alpha were upregulated on Ambroxol-PEG in relation to Control at 07 days (p < 0.05). Ambroxol 57-65 tumor necrosis factor Rattus norvegicus 27-36 35487151-0 2022 Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2. Ambroxol 24-32 angiotensin converting enzyme 2 Homo sapiens 150-181 35179198-0 2022 Ambroxol reverses tau and alpha-synuclein accumulation in a cholinergic N370S GBA1 mutation model. Ambroxol 0-8 microtubule associated protein tau Homo sapiens 18-21 35580314-5 2022 Ambroxol is a commercially available inhibitor of Nav1.8, a crucial player in the pathophysiology of neuropathic pain, and Nav1.7, a particularly exciting target for the treatment of chronic pain. Ambroxol 0-8 sodium voltage-gated channel alpha subunit 10 Homo sapiens 50-56 35580314-5 2022 Ambroxol is a commercially available inhibitor of Nav1.8, a crucial player in the pathophysiology of neuropathic pain, and Nav1.7, a particularly exciting target for the treatment of chronic pain. Ambroxol 0-8 sodium voltage-gated channel alpha subunit 9 Homo sapiens 123-129 35179198-0 2022 Ambroxol reverses tau and alpha-synuclein accumulation in a cholinergic N370S GBA1 mutation model. Ambroxol 0-8 synuclein alpha Homo sapiens 26-41 35179198-0 2022 Ambroxol reverses tau and alpha-synuclein accumulation in a cholinergic N370S GBA1 mutation model. Ambroxol 0-8 glucosylceramidase beta Homo sapiens 78-82 35179198-10 2022 Ambroxol significantly enhanced GCase activity and decreased both tau and alpha-synuclein levels in cholinergic neurons. Ambroxol 0-8 microtubule associated protein tau Homo sapiens 66-69 35179198-10 2022 Ambroxol significantly enhanced GCase activity and decreased both tau and alpha-synuclein levels in cholinergic neurons. Ambroxol 0-8 synuclein alpha Homo sapiens 74-89 35090309-11 2022 In the conjunctival tissue, significant decrease was seen in TNF-alpha (p < 0.01) and IL-8 (p (unilateral) < 0.05) concentrations in ambroxol group, and significant increase in MUC5AC concentration (p < 0.01) in ambroxol group as well. Ambroxol 133-141 tumor necrosis factor Oryctolagus cuniculus 61-70 35090309-11 2022 In the conjunctival tissue, significant decrease was seen in TNF-alpha (p < 0.01) and IL-8 (p (unilateral) < 0.05) concentrations in ambroxol group, and significant increase in MUC5AC concentration (p < 0.01) in ambroxol group as well. Ambroxol 133-141 interleukin-8 Oryctolagus cuniculus 86-90 35420884-1 2022 OBJECTIVES: The aim of the study is to examine the effect of Ambroxol on TNF-alpha and IL-1beta released after liver ischemia-reperfusion injury. Ambroxol 61-69 tumor necrosis factor Rattus norvegicus 73-82 35420884-1 2022 OBJECTIVES: The aim of the study is to examine the effect of Ambroxol on TNF-alpha and IL-1beta released after liver ischemia-reperfusion injury. Ambroxol 61-69 interleukin 1 alpha Rattus norvegicus 87-95 35420884-11 2022 CONCLUSION: It was determined that Ambroxol treatment suppressed the production of pro-inflammatory cytokines TNF-alpha and IL-1beta in rats undergoing hepatic ischemia reperfusion (Tab. Ambroxol 35-43 tumor necrosis factor Rattus norvegicus 110-119 35420884-11 2022 CONCLUSION: It was determined that Ambroxol treatment suppressed the production of pro-inflammatory cytokines TNF-alpha and IL-1beta in rats undergoing hepatic ischemia reperfusion (Tab. Ambroxol 35-43 interleukin 1 alpha Rattus norvegicus 124-132 35242650-0 2022 Efficacy of phentolamine combined with ambroxol aerosol inhalation in the treatment of pediatric severe pneumonia and its effect on serum IL-10 and CRP levels. Ambroxol 39-47 interleukin 10 Homo sapiens 138-143 35242650-0 2022 Efficacy of phentolamine combined with ambroxol aerosol inhalation in the treatment of pediatric severe pneumonia and its effect on serum IL-10 and CRP levels. Ambroxol 39-47 C-reactive protein Homo sapiens 148-151 35242650-1 2022 Background: The aim of the present study was to determine the therapeutic effect of phentolamine combined with Ambroxol aerosol inhalation on pediatric severe pneumonia and its effect on serum interleukin-10 (IL-10) and C-reactive protein (CRP) levels. Ambroxol 111-119 interleukin 10 Homo sapiens 193-207 35242650-1 2022 Background: The aim of the present study was to determine the therapeutic effect of phentolamine combined with Ambroxol aerosol inhalation on pediatric severe pneumonia and its effect on serum interleukin-10 (IL-10) and C-reactive protein (CRP) levels. Ambroxol 111-119 interleukin 10 Homo sapiens 209-214 35242650-1 2022 Background: The aim of the present study was to determine the therapeutic effect of phentolamine combined with Ambroxol aerosol inhalation on pediatric severe pneumonia and its effect on serum interleukin-10 (IL-10) and C-reactive protein (CRP) levels. Ambroxol 111-119 C-reactive protein Homo sapiens 220-238 35242650-1 2022 Background: The aim of the present study was to determine the therapeutic effect of phentolamine combined with Ambroxol aerosol inhalation on pediatric severe pneumonia and its effect on serum interleukin-10 (IL-10) and C-reactive protein (CRP) levels. Ambroxol 111-119 C-reactive protein Homo sapiens 240-243 3449066-2 1987 Studies demonstrating the elimination of radioactive particles during a 7-day course of therapy with 3 x 30 mg ambroxol or 4 x 1 capsule. Ambroxol 111-119 olfactory receptor family 4 subfamily X member 1 Homo sapiens 120-128 3552853-9 1987 Related to a maximum duration of pregnancy of 34 weeks, RDS morbidity after Ambroxol therapy was 18.2% (2 out of 11), as opposed to 35.7% (5 out of 14) after betamethasone treatment. Ambroxol 76-84 peripherin 2 Homo sapiens 56-59 3552853-10 1987 The results confirm that antenatal administration of Ambroxol can bring about a reduction in neonatal RDS corresponding to that achieved with betamethasone therapy. Ambroxol 53-61 peripherin 2 Homo sapiens 102-105 6548163-0 1984 Cord blood prolactin and thyroid hormone levels after antenatal administration of betamethasone or ambroxol for prevention of respiratory distress syndrome (RDS). Ambroxol 99-107 prolactin Homo sapiens 11-20 3515786-1 1986 In a multicenter, randomized double-blind study, the effect of Betamethasone and Ambroxol, both used for prenatal prevention of RDS in premature and newborn infants, is compared in a total of 185 patients with premature labour or an induced termination of pregnancy between the 28 and 36th week of gestation. Ambroxol 81-89 peripherin 2 Homo sapiens 128-131 3515786-6 1986 RDS morbidity, established by a standardized evaluation of the infants considering X-ray, clinical and blood-gas analyses findings, is 9% (7 out of 79 infants) in the Ambroxol group, and 6% (5 out of 86 infants) in the Betamethasone group. Ambroxol 167-175 peripherin 2 Homo sapiens 0-3 3518290-2 1986 Stimulation of the surfactant production in fetal cells by ambroxol (metabolite VIII of bromhexine) has been investigated in human and animal experiments. Ambroxol 59-67 cytochrome c oxidase subunit 8A Homo sapiens 80-84 6478010-2 1984 The aim of this study was to compare PMN functions in two groups of premature infants whose mothers had received betamethasone or ambroxol for prevention of RDS. Ambroxol 130-138 peripherin 2 Homo sapiens 157-160